839
Participants
Start Date
March 10, 2019
Primary Completion Date
October 21, 2020
Study Completion Date
October 21, 2020
Liraglutide
Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. Patients will be treated according to the Iranian label for Victoza®, following routine clinical practice and at the discretion of the study doctor. The study doctor will determine the intended maintenance dose of Victoza®, as well as any changes to the maintenance dose thereafter. The physician's decision to initiate treatment with Victoza® is clearly separate from the opportunity to include the patient in the study.
Novo Nordisk Investigational Site, Ahvāz
Novo Nordisk Investigational Site, Ardabil
Novo Nordisk Investigational Site, Babol
Novo Nordisk Investigational Site, Gorgan
Novo Nordisk Investigational Site, Hamadan
Novo Nordisk Investigational Site, Hormozgan
Novo Nordisk Investigational Site, Isfahan
Novo Nordisk Investigational Site, Islamshahr
Novo Nordisk Investigational Site, Karaj
Novo Nordisk Investigational Site, Kerman
Novo Nordisk Investigational Site, Mashahd
Novo Nordisk Investigational Site, Mashhad
Novo Nordisk Investigational Site, Sari
Novo Nordisk Investigational Site, Shiraz
Novo Nordisk Investigational Site, Tehran
Novo Nordisk Investigational Site, Yazd
Lead Sponsor
Novo Nordisk A/S
INDUSTRY